An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-516754-22-00

Acronym

GB002-2102

Enrollment

Registered

2024-11-06

Start date

2021-07-14

Completion date

Unknown

Last updated

2025-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension (PAH)

Brief summary

Incidence of treatment-emergent adverse events (TEAEs)

Detailed description

Change in the distance achieved on six-minute walk test (6MWT), (Δ6MWD)

Interventions

DRUGGB002

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Incidence of treatment-emergent adverse events (TEAEs)	—

Secondary

Measure	Time frame
Change in the distance achieved on six-minute walk test (6MWT), (Δ6MWD)	—

Countries

Czechia, Germany, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026